Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • eli lilly

    Tag: eli lilly

    You Searched For "eli lilly"
    Lilly gets USFDA nod for Taltz(ixekizumab) for Pediatric Patients with Moderate to Severe Plaque Psoriasis

    Lilly gets USFDA nod for Taltz(ixekizumab) for Pediatric Patients with Moderate to Severe Plaque Psoriasis

    Medical Dialogues Bureau1 April 2020 7:00 AM GMT
    Indianapolis: Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License...
    Eli Lilly delays its clinical trials during Coronavirus pandemic

    Eli Lilly delays its clinical trials during Coronavirus pandemic

    Medical Dialogues Bureau25 March 2020 9:30 AM GMT
    Indianapolis: Eli Lilly and Company has provided an update on the company's clinical trial activities in light of the COVID-19 pandemic. The company...
    Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for Alopecia Areata

    Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for Alopecia Areata

    Medical Dialogues Bureau19 March 2020 7:26 AM GMT
    Baricitinib is currently approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).
    AbCellera, Eli Lilly join hands for Antibody Therapies for COVID-19

    AbCellera, Eli Lilly join hands for Antibody Therapies for COVID-19

    Medical Dialogues Bureau13 March 2020 3:30 AM GMT
    Vancouver and Indianapolis: AbCellera and Eli Lilly and Company have recently announced that they have entered into an agreement to co-develop...
    USFDA accepts regulatory submission for tanezumab for management of chronic pain  due to osteoarthritis

    USFDA accepts regulatory submission for tanezumab for management of chronic pain due to osteoarthritis

    Medical Dialogues Bureau7 March 2020 4:30 AM GMT
    Tanezumab is a monoclonal antibody that is part of an investigational class of non-opioid chronic pain medications known as nerve growth factor (NGF)...
    FDA Advisory approves Lillys CYRAMZA (ramucirumab) for type of lung Cancer

    FDA Advisory approves Lilly's CYRAMZA (ramucirumab) for type of lung Cancer

    Medical Dialogues Bureau1 March 2020 8:30 AM GMT
    The ODAC considered the safety and efficacy data from the Phase 3 RELAY trial, which is the basis for the CYRAMZA supplemental Biologics License...
    Drugmakers including Novartis, Roche slash prices by 61pc in China to get on reimbursement list

    Drugmakers including Novartis, Roche slash prices by 61pc in China to get on reimbursement list

    Medical Dialogues Bureau29 Nov 2019 3:45 AM GMT
    Seventy new drugs such as Roche's breast cancer treatment Pertuzumab, sold under the trade name Perjeta, Novartis's dermatitis treatment Omalizumab,...
    Novo Nordisk wins USFDA nod for oral diabetes drug Rybelsus

    Novo Nordisk wins USFDA nod for oral diabetes drug Rybelsus

    Medical Dialogues Bureau23 Sep 2019 8:46 AM GMT
    Novo Nordisk did not disclose what it plans to charge for the new oral treatment, called Rybelsus, but said it would be "competitively priced" with...
    Mylan gets tentative USFDA nod for generic of Eli Lilly lung cancer drug Alimta

    Mylan gets tentative USFDA nod for generic of Eli Lilly lung cancer drug Alimta

    Medical Dialogues Bureau31 Aug 2019 4:00 AM GMT
    Alimta is Lilly's third biggest-selling drug. The Indianapolis-based drugmaker reported second-quarter sales of $577.8 million for the medicine.U.S:...
    Lupin unveils generic version of Prozac tablets in US

    Lupin unveils generic version of Prozac tablets in US

    Medical Dialogues Bureau24 Aug 2019 4:15 AM GMT
    Fluoxetine tablet is a generic version of Eli Lilly and Company's Prozac tablets in the same strengths, Lupin said.Mumba: Pharma major Lupin Limited...
    Roche names Eli Lilly executive Levi Garraway as chief medical officer

    Roche names Eli Lilly executive Levi Garraway as chief medical officer

    Medical Dialogues Bureau20 Aug 2019 3:30 AM GMT
    Levi Garraway, most recently Eli Lilly's senior vice president, oncology research and development and Lilly research laboratories novel target...
    AbbVie wins USFDA nod for new rheumatoid arthritis drug priced at Rs 41 lakh per year

    AbbVie wins USFDA nod for new rheumatoid arthritis drug priced at Rs 41 lakh per year

    Medical Dialogues Bureau18 Aug 2019 4:06 AM GMT
    A four-week supply of Humira, the world's best-selling medicine, has a list price of about $5,174, amounting to more than $60,000 for a year.U.S:...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier

    This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

    Search only trustworthy HONcode health websites:

    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

    © 2020 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    X